Joshua Anderson

One Small Step For Nektar Therapeutics, One Giant Leap For The Fight Against Prescription Drug Abuse

On Wednesday, at the 75th Annual Meeting of the College on Problems of Drug Dependence, Nektar Therapeutics (NASDAQ:NKTR) announced positive results for the human abuse liability study for NKTR-181 which is a very promising new drug candidate in Nektar's pipeline that is being developed as an analgesic for the treatment of chronic pain. According to Nektar's President and CEO Howard Robin, "The NKTR-181 molecule has been designed to enter the CNS slowly to reduce the dopamine rush and its associated euphoria that lead to the abuse of and addiction to current opioid analgesics." Read about the results here. In other words NKTR-181 is designed to be the first non-addictive opioid painkiller.

The problem of addiction and abuse...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details